This website uses cookies

This website uses cookies to improve user experience. By using our website you consent to all cookies in accordance with our Cookie Policy.

Groups

Scientific Career History

PD Dr. med. Juliane Walz née Stickel:

Education and Professional Experience

   
Since 2017 Medical specialist for internal medicine and hematology and oncology, Department of Hematology and Oncology, University of Tübingen
2011 - 2017 Resident Department of Hematology and Oncology, University of Tübingen
2009 - 2010 Clinical fellow, University of Tübingen and Kantonspital St Gallen (Switzerland)
2004 - 2010 Medical school, University of Tübingen (Grade: 1.5, very good)

Scientific Career

   
Since 2012 Junior research group leader (Department of Hematology and Oncology and Department of Immunology Tübingen)
2007 - 2011 Doctoral thesis at the department of Immunology Tübingen: “Tumor antigens and HLA class I ligands in tumors and metastases of renal cell carcinoma” (summa cum laude)

 Scholarships, Awards, Qualifications  

Since 2015  Member of the German Society of Hematology and Medical Oncology
2007 - 2008 Member of the graduate school 794 (dissertation fund) “cellular mechanisms of immune associated processes”, University of Tübingen
   
2017 Poster Price of the University of Tübingen, Forschungskolloquium
2016 Young Investigator Award DGHO Leipzig
2015 Württembergischer Krebspreis, Nachwuchspreis
2015 Poster Price DGHO Basel
2014 Abstract Achievement Award American Society of Hematology
2013 Abstract Achievement Award American Society of Hematology
2012 Abstract Achievement Award American Society of Hematology
2011 Ludolf Krehl Dissertation Award of the Süddeutschen Gesellschaft für Innere Medizin
2011 Dissertation Award of the Eberhard Karls Universität Tübingen

 Patents

2015 T-cell epitopes fort he immunotherapy of myeloma Priority application: GB1511191
2014 Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (CLL)” Priority application: UK Nr. 1411037.3 und US 62/014,849
2014 Novel immunotherapy against several tumors of the blood, such as acute myeloid leukemia (AML) Priority application: UK Nr. 1408255.6 und US 61/990,980